Even at the molecular level, the identification of subtypes including the estrogen receptor positive subtype (ER+; the 70% of cases of metastatic disease), human epidermal growth receptor-2 overexpressed (HER2+) tumors and triple-negative breast cancer (TNBC) show substantial differences in glucose metabolism [9]. Here, ESR1 is linked to triple-negative breast carcinoma.